Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 7Neoplasms 5Adenocarcinoma of Lung 5Lymphoma, Large-Cell, Anaplastic 4Neuroblastoma 3Neoplasm Metastasis 3Hematologic Neoplasms 3Granuloma, Plasma Cell 3Melanoma 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Lymphoma, B-Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1ALK-positive Advanced Tumors 1

Interventions

regorafenib 1entrectinib 1ceritinib 1capmatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Noonan Syndrome 6 × ceritinib × Clear all
NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated
1 enrolled 7 charts
Dermatologic

Noonan Syndrome 6, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡